Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment.

Zakaria AlameddineRacha Abi MelhemReem DimachkieHussein RabahHamed ChehabMichel El KhouryFaris QaqishDimitre StefanovSuzanne El-Sayegh

Published in: Journal of clinical medicine (2023)

Vedolizumab use was associated with an increased risk of nephrolithiasis. The use of two or more biologic drugs also increased the risk compared to no biologic treatment.

Keyphrases

rheumatoid arthritis
patients with inflammatory bowel disease
combination therapy
replacement therapy